Agents and Actions

, Volume 28, Issue 1–2, pp 108–114 | Cite as

Prostaglandin E2 prevents diclofenac-induced enhancement of histamine release and inflammation evoked byin vivo challenge with compound 48/80 in the hamster cheek pouch

  • J. Raud
  • A. Sydbom
  • S. -E. Dahlén
  • P. Hedqvist
Inflammation and Immunomodulation


Based on observations obtained by the use of intravital microscopy, we report that prostaglandins, (PGs) can exert inhibitory effects on mast cell-dependent inflammation. Thus, the PG-synthesis inhibitors diclofenac and indomethacin potentiated extravasation of plasma evoked by challenge with the mast cell secretagogue compound 48/80. Although the plasma leakage induced by compound 48/80 was in large mediated by histamine, neither diclofenac nor indomethacin potentiated the plasma leakage caused by exogenous histamine. These findings indicated that endogenous PGs inhibited the mast cell-dependent reaction at the level of mediator release. This mode of action was confirmed, as diclofenac was found to enhance thein vivo release of histamine that ensued challenge with compound 48/80. Moreover, the enhancement of the response to compound 48/80 observed after diclofenac treatment was prevented by local administration of PGE2 (30 nM). This inhibition included both the histamine release and the plasma leakage. In addition, diclofenac enhanced the leukocyte emigration after compound 48/80 challenge, and PGE2 reversed also this effect, suggesting that endogenous PGs (e.g. PGE2) also inhibited the release of chemotactic, mediators.


Histamine Prostaglandin Indomethacin PGE2 Histamine Release 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    J. Raud, S.-E. Dahlén, A. Sydbom, L. Lindbom and P. Hedqvist,Enhancement of acute allergic inflammation by indomethacin is reversed by prostaglandin E 2:Apparent correlation with in vivo modulation of mediator release. Proc. Natl. Acad. Sci. USA85, 2315–2319 (1988).PubMedGoogle Scholar
  2. [2]
    J. Raud, S.-E. Dahlén, G. Smedegård and P. Hedqvist,An intravital microscopic model for mast cell-dependent inflammation in the hamster cheek pouch. Acta Physiol. Scand.135, 95–105 (1989).PubMedGoogle Scholar
  3. [3]
    J. Raud, L. Lindbom, S.-E. Dahlén and P. Hedqvist.Periarteriolar localization of mast cells promotes oriented interstitial migration of leukocytes in the hamster cheek pouch. Am. J. Pathol.134, 161–169 (1989).PubMedGoogle Scholar
  4. [4]
    W. D. M. Paton,Compound 48/80: A potent histamine liberator. Br. J. Pharmacol.6, 499–508 (1951).PubMedGoogle Scholar
  5. [5]
    J. Björk, G. Smedegård, E. Svensjö and K.-E. Arfors,The use of the hamster cheek pouch for intravital microscopy studies of microvascular events. Prog. Appl. Microcirc.6, 41–53 (1984).Google Scholar
  6. [6]
    E. Svensjö, K.-E. Arfors, G. Arturson and G. Rutili,The hamster cheek pouch preparation as a model for studies of macromolecular permeability of the microcirculation. Upsala J. Med. Sci.83, 71–79 (1978).PubMedGoogle Scholar
  7. [7]
    B.R. Duling,The preparation and use of the hamster cheek pouch for studies of the microcirculation. Microvasc. Res.,5, 423–429, (1973).PubMedGoogle Scholar
  8. [8]
    P.A. Shore, A. Burkhalter and V.H. Cohn,A method for the fluorometric assay of histamine in tissues. J. Pharmacol. Exp. Ther.127, 182–186 (1959).PubMedGoogle Scholar
  9. [9]
    L.M. Lichtenstein and H.R. Bourne,Inhibition of allergic histamine release by histamine and other agents which stimulate adenyl cyclase. InBiochemistry of Acute Allergic Reactions (Ed. K.F. Austen and E.L. Becker) pp. 161–174, Blackwell, Oxford, 1971.Google Scholar
  10. [10]
    J.L. Walker,The regulatory function of prostaglandins in the release of histamine and SRS-A from passively sensitized human lung tissue. InAdvances in the Biosciences, vol. 9. (Eds. S. Bergström and S. Bernhard) pp. 235–240, Pergamon Press, Vieweg 1973.Google Scholar
  11. [11]
    M. Kaliner and K.F. Austen,Cyclic AMP, ATP, and reversed anaphylactic histamine release from rat mast cells. J. Immunol.112, 664–674 (1974).PubMedGoogle Scholar
  12. [12]
    M. Hitchocock,Effect of inhibitors of prostaglandin synthesis and prostaglandin E 2 and F on the immunologic release of mediators of inflammation from actively sensitized guinea-pig lung. J. Pharmacol. Exp. Ther.207, 630–640 (1978).PubMedGoogle Scholar
  13. [13]
    E.A. Ham, D.D. Soderman, M.E. Zanetti, H.W. Dougherty, E. McCauley and F.A. Kuehl J.R.,Inhibition by prostaglandins of leukotriene B 4 release from activated neutrophils. Proc. Natl. Acad. Sci. USA80, 4349–4353 (1983).PubMedGoogle Scholar
  14. [14]
    T.H. Lee, E. Israel, J.M. Drazen, A.G. Leitch, J. Ravalese III, E.J. Corey, D.R. Robinson, R.A. Lewis and K.F. Austen,Enhancement of plasma levels of biologically active leukotriene B compounds during anaphylaxis in guinea pigs pretreated by indomethacin or by a fish oil-enriched diet. J. Immunol.136, 2575–2582 (1986).PubMedGoogle Scholar
  15. [15]
    R. Levi, G. Allan and H. Zavecz,Prostaglandins and cardiac acaphylaxis. Life Sci.18, 1255–1264 (1976).PubMedGoogle Scholar
  16. [16]
    T. Okazaki, V.S. Ilea, N.A. Rosario, R.E. Reisman, C.E. Arbesman, J.B. Lee and E. Middleton Jr,Regulatory role of prostaglandin, E in allergic histamine release with observations on the responsiveness of basophil leukocytes and the effect of acetylsalicylic acid. J. Allergy Clin. Immunol.60, 360–366 (1977).PubMedGoogle Scholar
  17. [17]
    D.M. Engineer, U. Niederhauser, P.J. Piper and P. Sirois,Release of mediators of anaphylaxis: Inhibition of prostaglandin synthesis and the modification of release of slow reacting substance of anaphylaxis and histamine. Br. J. Pharmacol.62, 61–66 (1978).PubMedGoogle Scholar
  18. [18]
    T.J. Williams,Interactions between prostaglandins, leukotrienes and other mediators of inflammation. Br. Med. Bull.39, 239–242 (1983).PubMedGoogle Scholar
  19. [19]
    S.H. Ferreira and J.R. Vane,Mode of action of antiinflammatory agents which are prostaglandin synthetase inhibitors. InAnti-Inflammatory Drugs (Eds J.R. Vane and S.H. Ferreira) pp. 348–398, Springer, Berlin 1979.Google Scholar
  20. [20]
    G.A. Higgs, K.E. Eakins, K.G. Mugridge, S. Moncada and J.R. Vane,The effects of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation. Eur. J. Pharmacol.66, 81–86 (1980).PubMedGoogle Scholar
  21. [21]
    P. Hedqvist, S.-E. Dahlén and U. Palmertz,Leukotriene dependent airway anaphylaxis in guinea pigs. Prostaglandins28, 605–608 (1984).Google Scholar
  22. [22]
    C.N. Ellis, J.D. Fallon, S. Kang, E.E. Vanderveen and J.J. Voorhees,Topical application of nonsteroidal anti-inflammatory drugs prevents vehicle-induced improvement of psoriasis. J. Am. Acad. Dermatol.14, 39–43 (1986).PubMedGoogle Scholar
  23. [23]
    J. Björk and G. Smedegard,Immune-complex-induced, inflammatory reaction studied by intravital microscopy: Role of histamine and arachidonic acid metabolites. Inflammation11, 47–58 (1987).PubMedGoogle Scholar
  24. [24]
    C. Lundberg and B. Gerdin,The inflammatory reaction in an experimental model of open wounds in the rat. The effect of arachidonic acid metabolites. Eur. J. Pharmacol.97, 229–238 (1984).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1989

Authors and Affiliations

  • J. Raud
    • 1
    • 3
  • A. Sydbom
    • 2
  • S. -E. Dahlén
    • 1
    • 3
  • P. Hedqvist
    • 1
    • 3
  1. 1.Department of Physiology IKarolinska InstitutetStockholmSweden
  2. 2.Department of PharmacologyKarolinska InstitutetStockholmSweden
  3. 3.Department of Institute of Environmental MedicineKarolinska InstitutetStockholmSweden

Personalised recommendations